Overview
Measurable residual disease (MRD) testing plays a vital role in personalizing treatment for B-ALL patients, offering insights into disease status and prognosis. This study uses real-world data to examine the use of MRD testing, including the timing and frequency of testing, in Philadelphia-negative B-cell acute lymphoblastic leukemia (B-ALL) and its impact on patient outcomes.
Using the Flatiron Health Research Database, researchers assessed over 500 patients with B-ALL and found that while most receive MRD testing, differences in frequency, methodology, and sensitivity highlight the need for standardized practice. Specifically, persistent MRD positivity was associated with significantly worse survival, emphasizing its prognostic value. Timing of MRD testing was not associated with survival, suggesting the need to identify an optimal testing window.
Why this matters
This study underscores the importance of MRD testing in improving treatment outcomes and survival rates, clearly identifying its role as a prognostic marker and supporting its broader adoption as a standard practice in managing B-ALL. The findings contribute to the advancement of precision medicine, ensuring that patients receive the most appropriate and effective testing and therapies.